Potential $95 million Ultragenyx IPO leads biotech class of '14

Rare disease drug developer Ultragenyx Pharmaceutical Inc. is expected to hit the market next week — the first of a new wave of biotech initial public offerings — with an IPO that could raise nearly $95 million...